This new law permits the analysis of different government datasets to guide policy decisions and to better understand the opioid epidemic. Recently, a groundbreaking report highlighting the current state of the crisis was released as part of this effort. Led by the Department of Public Health (DPH), the Chapter 55 analysis.
The opioid epidemic won’t be solved overnight, and there’s no easy solution to make this problem disappear. However, there are signs of hope and a turning tide.
Similar to diabetes or cancer, addiction is a complex disease impacted by certain risk factors like behavior and family history. This disease is also more widespread than some may realize — according to a study from the Substance Abuse and Mental Health Services Administration (SAMHSA), nearly 1 in 12 Americans over the age of 12 have a substance abuse disorder.
It is not surprising, then, that until 2012 the NYPD—a famously data-oriented municipal police department, and America's largest—was not routinely monitoring death data for citywide trends relevant to the opioid epidemic. Those records were one of the first datasets RxStat coordinators used to bring.
For example, RxStat helped incorporate drug overdoses into the data analytics system that monitors reports from city emergency rooms. The team identified a lack of resources among local service agencies, so the department provided naloxone (Narcan) training and 1200 kits. From the effort’s early days, when agencies understood little about the city’s overdose problem, RxStat has evolved to generate actionable information and shape city policy, said Denise Paone, an RxStat principal and director of research and surveillance for the Department of Health and Mental Hygiene’s drug and alcohol bureau.
About 10% of prescriptions in the PDMP data set did not have a vendor-assigned drug category, and 20% of opioid prescriptions were missing data needed to calculate risk metrics. Using inclusive methods, 19,133,167 (>99.9%) of prescriptions in the PDMP data set were assigned a drug category. For the.
Next we used pharmaceutical class (PharmClasses field in the NDC drug reference table) to identify and assign pharmacologic drug categories to PDMP prescriptions. carisoprodol), or “not assigned.” If a prescription could not be linked to the NDC drug reference table, the study pharmacist used vendor classification and other data set information (e.g., information in the drug name) to assist in classification. We identified categories of interest based on known or suspected association with overdose risk, including benzodiazepines, non-benzodiazepine sedatives, opioids, other (e.g.
Despite these limitations, our experience and approach may help others prepare complete and consistent PDMP analytic data sets for pharmacoepidemiologic research.
PolicyMap has a lot of data on issues related to substance abuse, overdoses, the opioid epidemic and treatment services. The key datasets include drug overdose deaths per 100,000 people from the CDC, and drug and alcohol treatment facilities and buprenorphine physicians both available from the.
According to the CDC, since 1999, the number of overdose deaths involving opioids (prescription pain relievers and heroin) has quadrupled. This crisis has prompted calls to action from agencies and leaders across the nation, including a recent letter from the U.S. Surgeon General to every doctor in the country. At the current rate, almost 78 Americans die every single day from an opioid overdose. The numbers around this epidemic are astounding.
The opioid epidemic is an issue that is at the forefront of the nation’s mind right now, and PolicyMap is proud to be able to offer a simple-to-use tool that can help policymakers, advocates and other interested citizens to better understand this complex problem.
The mapping tool allows the user to see both the number and percentage of opioid claims at the local level in order to better understand how this critical issue impacts communities nationwide. By openly sharing data in a secure, broad, and interactive way, CMS and the U.S. Department of Health and.
retail prescription drug spending was about $325 billion. In 2015, Medicare Part D spending was $137 billion; U.S. Approximay 70% of Medicare beneficiaries have Medicare prescription drug coverage either from a Part D plan or a Medicare Advantage Plan offering Medicare prescription drug coverage. The mapping tool does not contain beneficiary information nor does the information presented in this tool indicate the quality or appropriateness of care provided by individual physicians or in a given geographic region.